{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:19:05Z","timestamp":1791357545715,"version":"4.3.1"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.yebeh.2021.107844","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:36Z","timestamp":1614211236000},"page":"107844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-1640","authenticated-orcid":false,"given":"Christian","family":"Brandt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynanne","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Uetrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107844_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000335612","article-title":"Epidemiology of cutaneous adverse drug reactions","volume":"97","author":"Mockenhaupt","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.yebeh.2021.107844_b0010","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0020","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.yebeh.2021.107844_b0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1203475417746148","article-title":"Toxic epidermal necrolysis spectrum management at Sunnybrook Health Sciences Centre: our multidisciplinary approach after review of the current evidence","volume":"22","author":"Mereniuk","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.yebeh.2021.107844_b0035","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.2014.839","article-title":"Recurrence and mortality following severe cutaneous adverse reactions","volume":"311","author":"Finkelstein","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2021.107844_b0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/0022-3859.81865","article-title":"Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study","volume":"57","author":"Barvaliya","year":"2011","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.yebeh.2021.107844_b0050","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0055","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0060","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0065","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamadermatol.2014.4844","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission","volume":"151","author":"Bequignon","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0070","first-page":"6","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40257-018-00416-4","article-title":"Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): how far have we come?","volume":"20","author":"Martinez-Cabriales","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0080","doi-asserted-by":"crossref","unstructured":"S.H. Kardaun M. Mockenhaupt J.C. Roujeau Comments on: DRESS syndrome J Am Acad Dermatol 2014;71:1000-.e2.","DOI":"10.1016\/j.jaad.2013.11.053"},{"key":"10.1016\/j.yebeh.2021.107844_b0085","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.mcna.2010.03.004","article-title":"Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome","volume":"94","author":"Kano","year":"2010","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.yebeh.2021.107844_b0090","first-page":"556","article-title":"Clinical features of drug-induced hypersensitivity syndrome in 38 patients","volume":"20","author":"Um","year":"2010","journal-title":"J Invest Allergol Clin Immunol"},{"key":"10.1016\/j.yebeh.2021.107844_b0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.iac.2009.04.007","article-title":"The variable clinical picture of drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug","volume":"29","author":"Kano","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.yebeh.2021.107844_b0100","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0105","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0110","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.2174\/1381612822666160928125152","article-title":"Severe drug hypersensitivity reactions: Clinical pattern, diagnosis, etiology and therapeutic options","volume":"22","author":"Paulmann","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.yebeh.2021.107844_b0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaad.2009.08.050","article-title":"Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients","volume":"63","author":"Ang","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"155","author":"Peyri\u00e8re","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0125","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.12783","article-title":"Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"170","author":"Chi","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0130","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/21548331.2018.1451205","article-title":"DRESS syndrome: a detailed insight","volume":"46","author":"Behera","year":"2018","journal-title":"Hosp Pract"},{"key":"10.1016\/j.yebeh.2021.107844_b0140","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2014.10.032","article-title":"Therapeutic management of DRESS: a retrospective study of 38 cases","volume":"72","author":"Funck-Brentano","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0145","doi-asserted-by":"crossref","first-page":"9095275","DOI":"10.1155\/2018\/9095275","article-title":"Eosinophils from physiology to disease: a comprehensive review","volume":"2018","author":"Ramirez","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.yebeh.2021.107844_b0150","doi-asserted-by":"crossref","first-page":"705","DOI":"10.12998\/wjcc.v7.i6.705","article-title":"Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome","volume":"7","author":"Martinez-Cabriales","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.yebeh.2021.107844_b0155","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2010.12.013","article-title":"Fulminant myocarditis as a late sequela of DRESS: two cases","volume":"65","author":"Bourgeois","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0160","doi-asserted-by":"crossref","first-page":"7863815","DOI":"10.1155\/2019\/7863815","article-title":"Pulmonary manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) Syndrome: a systematic review","volume":"2019","author":"Taweesedt","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.yebeh.2021.107844_b0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.145.1.67","article-title":"Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure","volume":"145","author":"Eshki","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0170","first-page":"301","article-title":"Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms","volume":"137","author":"Descamps","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00130832-200308000-00004","article-title":"Human herpesvirus 6 and drug allergy","volume":"3","author":"Hashimoto","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.yebeh.2021.107844_b0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2021.107844_b0185","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107844_b0190","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107844_b0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40261-019-00754-z","article-title":"Adverse cutaneous drug reactions associated with old- and new-generation antiepileptic drugs using the Japanese pharmacovigilance database","volume":"39","author":"Hosohata","year":"2019","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.yebeh.2021.107844_b0200","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/epi.13925","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs","volume":"58","author":"Frey","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107844_b0205","article-title":"Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008\u20132017","volume":"35","author":"Kim","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.yebeh.2021.107844_b0210","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4168\/aair.2019.11.5.709","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs: a nationwide registry-based study in Korea","volume":"11","author":"Park","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.yebeh.2021.107844_b0215","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaad.2012.10.017","article-title":"Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution","volume":"68","author":"Ushigome","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0220","first-page":"339","article-title":"DRESS syndrome associated with carbamazepine and phenytoin","volume":"14","author":"Allam","year":"2004","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0225","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/epi4.12053","article-title":"DRESS syndrome: a case of cross-reactivity with lacosamide?","volume":"2","author":"Fong","year":"2017","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2021.107844_b0230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ebcr.2017.06.003","article-title":"Drug-induced hypersensitivity syndrome caused by valproic acid as a monotherapy for epilepsy: first case report in Asian population","volume":"8","author":"Wu","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.yebeh.2021.107844_b0235","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/ane.13218","article-title":"Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate","volume":"141","author":"Rogin","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107844_b0240","unstructured":"XCOPRI\u00ae (cenobamate tablets), for oral use, CV [prescribing information]. SK Life Science, Inc., Paramus, NJ; 2020."},{"key":"10.1016\/j.yebeh.2021.107844_b0245","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107844_b0250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.yebeh.2021.107844_b0255","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/pr.113.007450","article-title":"Idiosyncratic adverse drug reactions: current concepts","volume":"65","author":"Uetrecht","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.yebeh.2021.107844_b0260","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40264-019-00818-1","article-title":"The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: focus on new discoveries","volume":"42","author":"Olteanu","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2021.107844_b0265","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.yebeh.2021.107844_b0270","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.yebeh.2021.107844_b0275","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107844_b0280","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.yebeh.2021.107844_b0285","doi-asserted-by":"crossref","first-page":"64","DOI":"10.12793\/tcp.2019.27.2.64","article-title":"Antiepileptic drug-induced severe cutaneous adverse reactions and HLA alleles: aA report of five cases with lymphocyte activation test","volume":"27","author":"Kim","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107844_b0290","first-page":"3399","article-title":"Association between HLA gene polymorphism and cutaneous adverse reactions caused by antiepileptic drugs","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.yebeh.2021.107844_b0295","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","article-title":"Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population","volume":"75","author":"Mushiroda","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2021.107844_b0300","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.seizure.2018.06.024","article-title":"Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis","volume":"60","author":"Deng","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107844_b0305","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1111\/epi.13498","article-title":"Genetic risk factors for antiepileptic drug-induced hypersensitivity reactions in Israeli populations","volume":"57","author":"Israel","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107844_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/J36S7D","article-title":"Association between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions: a systematic review and meta-analysis","volume":"21","author":"Tangamornsuksan","year":"2018","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.yebeh.2021.107844_b0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2018.12.011","article-title":"Association between HLA-A*3201 allele and oxcarbazepine-induced cutaneous adverse reactions in Eastern Han Chinese population","volume":"65","author":"Xu","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107844_b0320","doi-asserted-by":"crossref","first-page":"2489429","DOI":"10.1155\/2019\/2489429","article-title":"Erratum to \u201can updated review of the molecular mechanisms in drug hypersensitivity\u201d","volume":"2019","author":"Chen","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.yebeh.2021.107844_b0325","doi-asserted-by":"crossref","first-page":"6431694","DOI":"10.1155\/2018\/6431694","article-title":"An updated review of the molecular mechanisms in drug hypersensitivity","volume":"2018","author":"Chen","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.yebeh.2021.107844_b0330","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpt.683","article-title":"Pharmacogenomic advances in the prediction and prevention of cutaneous idiosyncratic drug reactions","volume":"102","author":"Pan","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2021.107844_b0335","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing","volume":"96","author":"Caudle","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2021.107844_b0340","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 Update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2021.107844_b0345","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/epi.12564","article-title":"Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions","volume":"55","author":"Amstutz","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107844_b0350","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107844_b0355","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1212\/WNL.0000000000001034","article-title":"Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions","volume":"83","author":"Chen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107844_b0360","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fphar.2020.00527","article-title":"Usage pattern of carbamazepine and associated severe cutaneous adverse reactions in Singapore following implementation of HLA-B*15:02 genotyping as standard-of-care","volume":"11","author":"Sung","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107844_b0365","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/epi.16053","article-title":"Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States","volume":"60","author":"Choi","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107844_b0370","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1212\/WNL.0b013e31826aac73","article-title":"Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore","volume":"79","author":"Dong","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107844_b0375","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaad.2019.04.040","article-title":"Knowledge and opinions among Canadian academic physicians regarding genetic screening to prevent severe cutaneous adverse drug reactions","volume":"81","author":"Chan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0380","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107844_b0385","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/all.13821","article-title":"HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS\/TEN in Europeans","volume":"74","author":"Mockenhaupt","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.yebeh.2021.107844_b0390","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2021.107844_b0395","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cpt.1190","article-title":"HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians","volume":"105","author":"Su","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2021.107844_b0400","doi-asserted-by":"crossref","first-page":"2780272","DOI":"10.1155\/2018\/2780272","article-title":"Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients","volume":"2018","author":"Sukasem","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.yebeh.2021.107844_b0405","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41467-019-11396-2","article-title":"Identification of drug-specific public TCR driving severe cutaneous adverse reactions","volume":"10","author":"Pan","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.yebeh.2021.107844_b0410","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/tx980249i","article-title":"New concepts in immunology relevant to idiosyncratic drug reactions: the \u201cdanger hypothesis\u201d and innate immune system","volume":"12","author":"Uetrecht","year":"1999","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.yebeh.2021.107844_b0415","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107844_b0420","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00002018-199818040-00004","article-title":"Safety review of adult clinical trial experience with lamotrigine","volume":"18","author":"Messenheimer","year":"1998","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2021.107844_b0425","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/jnnp.47.6.642","article-title":"Serum anticonvulsant concentrations and the risk of drug induced skin eruptions","volume":"47","author":"Chadwick","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107844_b0430","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2019.07.003","article-title":"Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting","volume":"72","author":"Fowler","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107844_b0435","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/YIC.0b013e32832775fe","article-title":"Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study","volume":"24","author":"Joe","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2021.107844_b0440","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1528-1167.2006.00423.x","article-title":"Predictors of lamotrigine-associated rash","volume":"47","author":"Hirsch","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107844_b0445","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/acs.chemrestox.6b00357","article-title":"How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction","volume":"30","author":"Cho","year":"2017","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.yebeh.2021.107844_b0450","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/tx034195a","article-title":"Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated","volume":"17","author":"Masson","year":"2004","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.yebeh.2021.107844_b0455","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107844_b0460","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107844_b0465","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107844_b0470","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0475","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.4.3.571","article-title":"Anticonvulsant hypersensitivity syndrome: a review","volume":"4","author":"Gogtay","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.yebeh.2021.107844_b0480","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14737175.2020.1707668","article-title":"The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection","volume":"20","author":"Verrotti","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2021.107844_b0485","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ACI.0000000000000546","article-title":"Making a diagnosis in severe cutaneous drug hypersensitivity reactions","volume":"19","author":"Ardern-Jones","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.yebeh.2021.107844_b0490","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/ICO.0b013e31823d02a8","article-title":"Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"31","author":"Hsu","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.yebeh.2021.107844_b0495","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0500","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0505","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0510","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches","volume":"137","author":"Gonzalez-Herrada","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0515","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.alit.2016.06.001","article-title":"A review of toxic epidermal necrolysis management in Japan","volume":"66","author":"Kinoshita","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.yebeh.2021.107844_b0520","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"issue":"709","key":"10.1016\/j.yebeh.2021.107844_b0525","first-page":"e1","article-title":"DRESS syndrome: part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0530","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00228-011-1005-8","article-title":"Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs","volume":"67","author":"Pereira de Silva","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107844_b0535","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.107844_b0540","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jdv.12419","article-title":"Recurrence of drug-induced reactions in DRESS patients","volume":"29","author":"Picard","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.yebeh.2021.107844_b0545","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0550","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/1346-8138.12770","article-title":"Sequelae in 145 patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR)","volume":"42","author":"Kano","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0555","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/abd1806-4841.20175190","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) and its relation with autoimmunity in a reference center in Mexico","volume":"92","author":"Matta","year":"2017","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.yebeh.2021.107844_b0560","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cpt.890","article-title":"Research directions in genetic predispositions to Stevens-Johnson syndrome \/ toxic epidermal necrolysis","volume":"103","author":"Manolio","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2021.107844_b0565","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamadermatol.2017.0160","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health working group","volume":"153","author":"Maverakis","year":"2017","journal-title":"JAMA Dermatol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:38:38Z","timestamp":1761503918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":113,"alternative-id":["S1525505021000780"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107844","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107844"}}